The National Institute of Allergy and Infectious Diseases, Radiation and Nuclear Countermeasures Program, was tasked by the United States Congress and the U.S. Department of Health and Human Services to identify and fund early-to-mid-stage development of medical countermeasures (MCMs) to treat radiation-induced injuries. In developing MCMs to treat various sub-syndromes (e.g., hematopoietic, gastrointestinal, lung), it is important to investigate whether a poly-pharmacy approach (i.e., drug cocktails) can provide additive benefits to mitigate injuries arising from the acute radiation syndrome (ARS). In addition, potential drug-drug interactions must be examined. For this reason, a workshop was held, which centered on understanding the current state of research investigating poly-pharmacy approaches to treat radiation injuries. The first session set the stage with an introduction to the concept of operations or support available for the response to a nuclear incident, as this is the key to any emergency response, including MCM availability and distribution. The second session followed the natural history of ARS in both humans and animal models to underscore the complexity of ARS and why a poly-pharmacy approach may be necessary. The third session featured talks from investigators conducting current MCM poly-pharmacy research. The meeting closed with a focus on regulatory considerations for the development of poly-pharmacy approaches or combination treatments for ARS.

美国国会和美国卫生与公共服务部委托国家过敏和传染病研究所、辐射和核对策计划确定并资助早期到中期的医疗对策 (MCM) 开发，以治疗辐射引起的损伤。在开发 MCM 来治疗各种亚综合征（例如造血、胃肠道、肺）时，重要的是研究多种药物方法（即药物鸡尾酒）是否可以提供额外的益处来减轻急性辐射综合征引起的损伤。辅助研究系统）。此外，必须检查潜在的药物相互作用。为此，举办了一次研讨会，重点是了解研究治疗放射损伤的多种药物方法的研究现状。第一场会议介绍了可用于响应核事故的操作或支持的概念，因为这是任何紧急响应的关键，包括 MCM 的可用性和分发。第二场会议跟踪了人类和动物模型中 ARS 的自然史，强调了 ARS 的复杂性以及为什么可能需要采用多种药物治疗方法。第三场会议的主题是进行当前 MCM 多药学研究的研究人员的演讲。会议结束时，重点讨论了针对 ARS 的多种药物方法或联合治疗方法开发的监管考虑。